TCD Capital (ex TheClubDeal)

TCD Capital manages two funds in Belgium & France investing in Tech, Life Sciences and Smart Living. We add value by processing strong applied governance principles when selecting and managing our investments and by gathering the necessary skills to grow the venture we ally with.

Jean-Marc Legrand

Founder and Managing Director

Nicolas Roberti

Executive Partner

17 past transactions

Vaxinano

Venture Round in 2024
Vaxinano is a biotechnology company focused on the preclinical and pharmaceutical development of vaccines and drug delivery systems for both humans and animals. Established in 2016, Vaxinano builds on 25 years of research and clinical trials related to vaccines, utilizing the patented technology of Pr Didier Betbeder. The company specializes in creating safe-by-design nanoparticles that adhere to green chemistry principles, which support the development of prophylactic and therapeutic vaccines for infectious diseases. Additionally, Vaxinano aids medical researchers in formulating drugs that activate biomolecules, proteins, and antigens, thereby facilitating innovative approaches to combat untreated viral, bacterial, and parasitic diseases.

Clouds of care

Venture Round in 2024
Clouds of Care is a consulting firm that assists HealthTech companies throughout their development process, from algorithm validation to medical device software. The company specializes in regulatory compliance and aims to identify and eliminate barriers to market entry, facilitating the faster delivery of innovative technologies to patients. By leveraging its expertise in quality assurance, regulatory requirements, and software development, Clouds of Care provides valuable support to HealthTech firms, helping them navigate complex challenges and accelerate their journey to successful product implementation.

Univercells

Series D in 2022
Univercells is a provider of biomanufacturing solutions focused on making biologics, including vaccines and therapeutics, more accessible and affordable. The company offers innovative technologies designed to reduce manufacturing costs significantly, achieving up to 90% savings on the cost of goods and over 75% in capital investment. Their approach utilizes single-use technologies and integrates three manufacturing steps—cell culture under perfusion, clarification, and capture—into a simulated continuous mode. Univercells also provides a range of biomanufacturing services, including scale-X hydro, scale-X carbo, and NevoLine, along with integrated support such as equipment confirmation, facility design, and bioprocess excellence. This comprehensive offering aids cell and gene therapy manufacturers in scaling their operations from research and development to commercial production, ultimately addressing global health challenges.

Flyx

Series A in 2022
Flyx is a SaaS-based platform that helps retail chains enhance customer engagement across various sectors, including food, grocery, and fuel. By offering user-friendly mobile and web applications, along with self-service kiosks and analytics dashboards, Flyx enables retailers to create a seamless omni-channel sales model. The platform focuses on maximizing value from each customer interaction, facilitating a loyalty experience that aims to increase sales and improve conversion rates for its clients.

Smartflats

Series A in 2021
Smartflats is a company that specializes in constructing and distributing a range of short-term rental apartments, offering clients the privacy and flexibility of a home combined with the comforts of a hotel. Founded in 2012 by Tarik Hennen and Alexandre Szmaj, Smartflats operates an online platform that allows users to book stylish accommodations in central urban locations. Guests enjoy various amenities, including keyless check-in, full-time concierge service, and essential in-apartment features such as wireless internet, TVs, coffee makers, irons, and hairdryers. In addition to accommodation, Smartflats facilitates food orders and transfer services, ensuring a comprehensive and convenient experience for its users.

Sortlist

Series B in 2021
Sortlist is an online platform designed to assist businesses in finding marketing and communication agencies that meet their specific needs. By utilizing a multi-criteria searching tool, Sortlist connects marketing managers with suitable partners quickly and efficiently, allowing them to focus on their core objectives. The platform is linked to professional networks and incorporates peer-to-peer recommendations, making the search process more effective for businesses of all sizes and sectors. With Sortlist, clients can streamline their search for service providers, ensuring they find the right match to achieve their marketing and communication goals.

Univercells

Series C in 2020
Univercells is a provider of biomanufacturing solutions focused on making biologics, including vaccines and therapeutics, more accessible and affordable. The company offers innovative technologies designed to reduce manufacturing costs significantly, achieving up to 90% savings on the cost of goods and over 75% in capital investment. Their approach utilizes single-use technologies and integrates three manufacturing steps—cell culture under perfusion, clarification, and capture—into a simulated continuous mode. Univercells also provides a range of biomanufacturing services, including scale-X hydro, scale-X carbo, and NevoLine, along with integrated support such as equipment confirmation, facility design, and bioprocess excellence. This comprehensive offering aids cell and gene therapy manufacturers in scaling their operations from research and development to commercial production, ultimately addressing global health challenges.

Univercells

Series C in 2020
Univercells is a provider of biomanufacturing solutions focused on making biologics, including vaccines and therapeutics, more accessible and affordable. The company offers innovative technologies designed to reduce manufacturing costs significantly, achieving up to 90% savings on the cost of goods and over 75% in capital investment. Their approach utilizes single-use technologies and integrates three manufacturing steps—cell culture under perfusion, clarification, and capture—into a simulated continuous mode. Univercells also provides a range of biomanufacturing services, including scale-X hydro, scale-X carbo, and NevoLine, along with integrated support such as equipment confirmation, facility design, and bioprocess excellence. This comprehensive offering aids cell and gene therapy manufacturers in scaling their operations from research and development to commercial production, ultimately addressing global health challenges.

Yust Group

Seed Round in 2019
Yust is a company that offers lodging and hospitality services. The business offers housing, activities, meals, drinks, and services with an emphasis on art and culture, enabling urban residents and visitors to meet others who share their interests and travel at their own pace.

Graftys

Series A in 2019
Graftys is an early-stage company based in Aix-en-Provence, France, specializing in advanced bone biologics. The company develops synthetic bone biomaterials specifically designed for reconstructive orthopedic surgery. Graftys offers a range of innovative and fully injectable calcium phosphate bone graft substitutes that are tailored for various clinical applications. By focusing on safety and quality, Graftys aims to provide effective solutions for patients undergoing bone reconstructive and trauma surgery.

Univercells

Series B in 2018
Univercells is a provider of biomanufacturing solutions focused on making biologics, including vaccines and therapeutics, more accessible and affordable. The company offers innovative technologies designed to reduce manufacturing costs significantly, achieving up to 90% savings on the cost of goods and over 75% in capital investment. Their approach utilizes single-use technologies and integrates three manufacturing steps—cell culture under perfusion, clarification, and capture—into a simulated continuous mode. Univercells also provides a range of biomanufacturing services, including scale-X hydro, scale-X carbo, and NevoLine, along with integrated support such as equipment confirmation, facility design, and bioprocess excellence. This comprehensive offering aids cell and gene therapy manufacturers in scaling their operations from research and development to commercial production, ultimately addressing global health challenges.

3D-Side

Series A in 2018
3D-Side is a medical technology company that specializes in developing three-dimensional cranial implants and solutions for bone surgery. Originating as a spin-off from UCL University, the company integrates advanced 3D software and additive manufacturing to assist surgeons in planning complex medical interventions. 3D-Side has established a comprehensive ISO13485 workflow aimed at enhancing efficiency and traceability in surgical procedures. Central to its operations is Customize, a web-based Software as a Service (SaaS) platform featuring three modules: a communication tool for surgeon interaction, a design program for creating custom instruments and implants, and a production management interface for overseeing just-in-time manufacturing. This innovative approach allows surgeons to send medical images, visualize 3D surgical plans, and monitor engineering work securely, ultimately ensuring that all preparations are completed promptly for successful surgeries. 3D-Side's technology enhances preoperative planning and aims to reduce operating times, contributing significantly to improved patient outcomes and surgical efficiency.

BCI Pharma

Series A in 2017
BCI Pharma is a biotechnology company that specializes in the design and synthesis of kinase inhibitor libraries. The firm focuses on developing innovative medicinal chemistry and screening technologies aimed at discovering selective and potent kinase inhibitors. BCI Pharma's research targets the treatment of various conditions, including inflammatory diseases, central nervous system disorders, cancer, and metabolic diseases. Through its advanced cell-based assays and kinase platform, the company aims to deliver effective therapies that meet the needs of patients and healthcare providers. BCI Pharma aspires to be a highly regarded entity among its patients, customers, investors, business partners, and the communities in which it operates.

BizMotica

Series A in 2017
Bezonia is a universal integration platform enabling people to orchestrate the most scalable technological ecosystems.

lawbox

Series A in 2017
Lawbox is an online platform designed to cater to the legal needs of entrepreneurs by providing a range of personalized legal documents. The service offers model contracts, letters, and other legal templates that have been validated by experienced lawyers. Users can customize these documents through a questionnaire tailored to their specific profiles, ensuring that the legal solutions are relevant and applicable to their unique situations. Lawbox aims to streamline the management of legal formalities, enabling clients to handle business operations, contracts, recruitment, brand protection, and dispute resolution efficiently. By simplifying the legal process, Lawbox also seeks to provide a faster and more cost-effective alternative to traditional legal services.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.